Vontobel Holding Ltd. Has $844,000 Stock Position in Haemonetics Corporation $HAE

Vontobel Holding Ltd. reduced its position in shares of Haemonetics Corporation (NYSE:HAE) by 28.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,310 shares of the medical instruments supplier’s stock after selling 4,529 shares during the period. Vontobel Holding Ltd.’s holdings in Haemonetics were worth $844,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in HAE. Dynamic Technology Lab Private Ltd acquired a new position in shares of Haemonetics during the first quarter worth $468,000. AQR Capital Management LLC increased its holdings in shares of Haemonetics by 591.6% during the first quarter. AQR Capital Management LLC now owns 174,565 shares of the medical instruments supplier’s stock worth $10,931,000 after buying an additional 149,325 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Haemonetics by 16.0% during the first quarter. Envestnet Asset Management Inc. now owns 55,746 shares of the medical instruments supplier’s stock worth $3,543,000 after buying an additional 7,678 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Haemonetics by 2.3% during the first quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock worth $68,355,000 after buying an additional 24,650 shares in the last quarter. Finally, Invenomic Capital Management LP acquired a new position in shares of Haemonetics during the first quarter worth $6,783,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HAE has been the topic of several analyst reports. Raymond James Financial cut shares of Haemonetics from a “strong-buy” rating to an “outperform” rating and reduced their price objective for the stock from $105.00 to $78.00 in a research note on Monday, August 11th. Citigroup reduced their price objective on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, October 7th. Barrington Research reissued an “outperform” rating and issued a $86.00 price objective on shares of Haemonetics in a research note on Tuesday, September 23rd. Robert W. Baird initiated coverage on shares of Haemonetics in a research report on Thursday, June 26th. They set an “outperform” rating and a $87.00 price target on the stock. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.89.

Haemonetics Stock Performance

Shares of HAE opened at $48.86 on Monday. The firm’s fifty day simple moving average is $53.66 and its two-hundred day simple moving average is $63.17. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $94.99. The stock has a market capitalization of $2.35 billion, a P/E ratio of 14.94, a price-to-earnings-growth ratio of 0.90 and a beta of 0.37. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The firm had revenue of $321.39 million for the quarter, compared to analyst estimates of $305.12 million. During the same quarter in the prior year, the business earned $1.02 earnings per share. The business’s quarterly revenue was down 4.4% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, analysts predict that Haemonetics Corporation will post 4.55 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.